Larger prospective randomized studies are required to distinguish the prognostic and predictive significance of EGFRvIII, HPV, p16, c-MET and EGFR GCN in SCCHN treated with EGFR inhibitors. The gene discussed is CDKN2A; the disease is head and neck squamous cell carcinoma.